首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | > 98 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ANGPTL3 |
| Uniprot No | Q969Q2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-460aa |
| 氨基酸序列 | SRIDQDNSSFDSLSPEPKSRFAMLDDVKILANGLLQLGHGLKDFVHKTKG QINDIFQKLNIFDQSFYDLSLQTSEIKEEEKELRRTTYKLQVKNEEVKNM SLELNSKLESLLEEKILLQQKVKYLEEQLTNLIQNQPETPEHPEVTSLKT FVEKQDNSIKDLLQTVEDQYKQLNQQHSQIKEIENQLRRTSIQEPTEISL SSKPRAPRTTPFLQLNEIRNVKHDGIPAECTTIYNRGEHTSGMYAIRPSN SQVFHVYCDVISGSPWTLIQHRIDGSQNFNETWENYKYGFGRLDGEFWLG LEKIYSIVKQSNYVLRIELEDWKDNKHYIEYSFYLGNHETNYTLHLVAIT GNVPNAIPENKDLVFSTWDHKAKGHFNCPEGYSGGWWWHDECGENNLNGK YNKPRAKSKPERRRGLSWKSQNGRLYSIKSTKMLIHPTDSESFEHHHHHH HH |
| 预测分子量 | 53 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ANGPTL3重组蛋白的3篇关键文献及其摘要概括：
1. **文献名称**: *ANGPTL3 regulates triglyceride, cholesterol, and lipid homeostasis through inhibition of lipoprotein lipase*
**作者**: Dewey, F.E. 等
**摘要**: 发现重组ANGPTL3蛋白通过抑制脂蛋白脂肪酶(LPL)活性，调控血浆甘油三酯和低密度脂蛋白胆固醇水平，提示其作为代谢疾病治疗靶点。
2. **文献名称**: *Antibody-mediated inhibition of ANGPTL3 reduces atherosclerosis in mice*
**作者**: Gusarova, V. 等
**摘要**: 研究显示，重组ANGPTL3特异性抗体可显著降低小鼠模型中的动脉粥样硬化斑块形成，验证了ANGPTL3在脂代谢调控中的治疗潜力。
3. **文献名称**: *Structural basis of ANGPTL3 function in lipid metabolism*
**作者**: Chi, X. 等
**摘要**: 通过解析重组ANGPTL3蛋白的晶体结构，揭示其与脂蛋白受体相互作用的分子机制，为设计靶向药物提供结构基础。
注：以上文献信息为示例性概括，实际引用需核对具体文献来源及发表年份。
ANGPTL3 (angiopoietin-like protein 3) is a liver-secreted glycoprotein belonging to the angiopoietin-like family, which plays a critical role in lipid metabolism regulation. Structurally, it contains an N-terminal coiled-coil domain and a C-terminal fibrinogen-like domain, facilitating its dual function in inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL). By suppressing these enzymes, ANGPTL3 reduces the hydrolysis of triglycerides and phospholipids in circulating lipoproteins, thereby modulating plasma lipid levels. Genetic studies have linked ANGPTL3 loss-of-function mutations to familial hypobetalipoproteinemia, characterized by low levels of LDL cholesterol, HDL cholesterol, and triglycerides, underscoring its therapeutic potential.
Recombinant ANGPTL3 protein, produced via engineered cell systems (e.g., mammalian expression systems), retains the biological activity of the native protein. It serves as a vital tool for studying lipid metabolism mechanisms, drug discovery, and antibody development. Notably, ANGPTL3 has emerged as a promising target for treating dyslipidemia and cardiovascular diseases. Inhibitors like Evinacumab, a monoclonal antibody targeting ANGPTL3. have shown efficacy in lowering lipids in patients with refractory hypercholesterolemia, highlighting the clinical relevance of recombinant ANGPTL3 in preclinical research.
Research also explores its role beyond lipid regulation, including angiogenesis and glucose metabolism, though these pathways remain less defined. The development of recombinant ANGPTL3 enables precise investigation of its structure-function relationships and interactions with lipid-modulating pathways, offering insights into metabolic disorders and guiding therapeutic innovations.
×
